Public Sector Pension Investment Board Sells 3,500 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Public Sector Pension Investment Board reduced its stake in Omnicell, Inc. (NASDAQ:OMCL) by 3.5% during the 3rd quarter, Holdings Channel.com reports. The firm owned 97,555 shares of the company’s stock after selling 3,500 shares during the period. Public Sector Pension Investment Board’s holdings in Omnicell were worth $4,253,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of OMCL. Assenagon Asset Management S.A. grew its stake in Omnicell by 61.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock valued at $16,240,000 after buying an additional 228,093 shares during the last quarter. Federated Hermes Inc. grew its position in shares of Omnicell by 1,113.6% in the second quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock valued at $26,830,000 after purchasing an additional 909,480 shares during the last quarter. Royce & Associates LP bought a new position in shares of Omnicell during the third quarter worth approximately $811,000. Liontrust Investment Partners LLP acquired a new stake in Omnicell during the 2nd quarter worth approximately $4,066,000. Finally, Intech Investment Management LLC bought a new stake in Omnicell in the 3rd quarter valued at $753,000. 97.70% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

OMCL has been the subject of a number of research reports. Bank of America reissued a “neutral” rating and set a $57.00 target price (up previously from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Barclays boosted their price objective on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Wells Fargo & Company raised their target price on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a report on Monday, October 14th. StockNews.com cut Omnicell from a “buy” rating to a “hold” rating in a research note on Wednesday, November 27th. Finally, Benchmark reaffirmed a “buy” rating and issued a $48.00 price target on shares of Omnicell in a research note on Wednesday, October 9th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Omnicell has an average rating of “Hold” and a consensus target price of $52.00.

Omnicell Stock Up 2.2 %

Shares of Omnicell stock opened at $47.61 on Tuesday. The company has a market cap of $2.21 billion, a PE ratio of -122.06, a price-to-earnings-growth ratio of 35.40 and a beta of 0.81. The business has a 50 day moving average price of $44.62 and a 200-day moving average price of $38.16. Omnicell, Inc. has a 52 week low of $25.12 and a 52 week high of $55.74.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.